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Functional activity and transmembrane
signaling mechanisms after
cryopreservation of human internal
mammary arteries
Else Müller-Schweinitzer, MD, Peter Stulz, MD, Heinz Striffeler, MD, and
Walter E. Haefeli, MD, Basel and Bern, Switzerland
Purpose: Cryopreserved human blood vessels are important tools in bypass surgery.
However, several in vitro studies have demonstrated diminished postthaw functional
activity. Therefore the aim of this study was to investigate the consequences of various
freezing/thawing protocols and the role of protein kinase C in the postthaw functional
activity of cryopreserved human arteries.
Methods: In vitro responses of frozen/thawed human internal mammary arteries
(IMA) were used to investigate the functional activity after thawing at 15°, 30°, and
100° C/min and after different prefreezing equilibration times (10, 60, 120, 240
minutes) with the cryomedium (Krebs-Henseleit solution containing 1.8 mol/L
dimethyl sulfoxide and 0.1 mol/L sucrose) at room temperature followed by cryo-
storage at -196° C.
Results: Prefreezing equilibration for 10 to 120 minutes diminished maximal a -adreno-
ceptor-mediated responses to noradrenaline to approximately 60%, and equilibration
for 240 minutes attenuated noradrenaline effects to less than 25% of that produced by
unfrozen controls. Contractile responses were slightly better when thawing was per-
formed at 15° C/min compared with 100° C/min. The postthaw sensitivity to direct
activation of protein kinase C by phorbol 12,13-dibutyrate was enhanced. Compared
with unfrozen tissues (pD2 = 7.36 ± 0.07, n = 32) maximal sensitization to phorbol
12,13-dibutyrate was observed in IMA that had been frozen after 60 minutes of equi-
libration with the cryomedium (pD2 = 8.31 ± 0.09, n = 30). Responses to phorbol
12,13-dibutyrate of cryopreserved IMA were highly susceptible to blockade of calcium
influx by nifedipine, whereas those of unfrozen IMA were resistant to nifedipine.
Against noradrenaline nifedipine was equipotent in cryopreserved (pD’2 = 7.75 ± 0.15,
n = 8) and unfrozen IMA (pD’2 = 7.70 ± 0.10, n = 6). Endothelium-dependent relax-
ant responses to acetylcholine were significantly attenuated after cryopreservation
(Emax = 26% ± 5%, n = 4) compared with unfrozen IMA (Emax = 71% ± 4%, n = 4, p <
0.001); endothelium-independent relaxant responses to sodium nitroprusside were
unchanged.
Conclusions: Cryopreservation of human IMA under the conditions applied in this
study (1) attenuated endothelial cell function and (2) induced an activation of pro-
tein kinase C, thereby increasing calcium influx through dihydropyridine-sensitive
calcium channels. These experimental data suggest that postoperative administration
of calcium channel blockers alone or combined with long-acting nitrates should
effectively prevent the development of spasms in arterial grafts. (J Vasc Surg
1998;27:528-37.)
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Because of its superior long-term patency rate
the human internal mammary artery (IMA) is
increasingly used for autologous coronary bypass
surgery.1 However, a limited percentage of all
patients undergoing coronary surgery require graft
substitutes because of previous bypass surgery or
other peripheral vascular disorders, and the search
for alternative coronary grafts has been intensified.
Cryopreserved homologous saphenous veins have
been one of these alternatives for coronary artery
bypass grafting. However, clinical observations sug-
gested that these veins have poor angiographic
patency.2 Against this background the use of cadav-
eric cryopreserved IMA as coronary bypass conduits
seems an attractive alternative. Recently, cryopreser-
vation has also become an important tool for the
storage of human vascular tissues in pharmacologic
research.3-5 These experiments have demonstrated
that the postthaw functional recovery of cryopre-
served isolated blood vessels is generally associated
with reduced contractile force, endothelial function,
and compliance.3,4 Furthermore it has been shown
that cryopreserved arteries may fracture during rapid
thawing, but not if rewarmed slowly.6,7
To date it is largely unknown which alterations
ultimately determine the net vascular function after
cryopreserved blood vessels are rewarmed. Therefore
the aim of our study was to investigate the conse-
quences of various freezing/thawing protocols and
whether the time of prefreezing exposure to the cry-
omedium could modify the postthaw functional
activity of cryopreserved human IMA. In addition,
changes in transmembrane signaling resulting from
the freezing/thawing process were assessed with the
protein kinase C (PKC) activator phorbol 12,13-
dibutyrate (PDBu).
MATERIAL AND METHODS
Storage methods. Internal mammary arteries
(10 to 20 mm long, inner diameter ≈ 1 mm) were
obtained during bypass surgery or were excised from
multiple organ donors after permission was obtained
from the local ethical committee. The preparations
were placed in Krebs-Henseleit (KH) solution (com-
position mmol/L: NaCl 118, KCl 4.7, MgSO4 1.2,
CaCl2 1.25, KH2PO4 1.2, NaHCO3 25, glucose 11,
ethylenediamine tetraacetic acid 0.03) at room tem-
perature and transported to the laboratory. The
arteries were cleaned of loose connective tissue and
used in organ bath studies either unfrozen within 20
hours after explantation or after cryopreservation.
For cryopreservation the arterial segments were sus-
pended in 2 ml liquid nitrogen storage ampoules
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(Life Technologies AG, Basel, Switzerland) filled
with KH solution containing 1.8 mol/L dimethyl
sulphoxide (Me2SO) and 0.1 mol/L sucrose. The
arteries were placed into the ampoules at different
times so that the tissues were exposed to the cry-
omedium for 10, 60, 120, and 240 minutes at room
temperature before being placed into a polystyrene
box (5 · 7 · 15 cm) and slowly frozen at a mean
cooling rate of approximately 1.3° C/min in a freez-
er maintained at -70° C. After approximately 2
hours or in rare cases on the next morning (after 20
hours at -70° C), the ampoules were transferred into
liquid nitrogen (-196° C) to be stored until use.
Before use the samples were thawed either rapidly at
approximately 100° C/min by placing the ampoules
for 4 minutes into a 40° C water bath (one-step
thawing), or thawing was preceded by exposure for
6 minutes to room temperature (two-step thawing)
at a mean thawing rate of approximately 30° C/min,
or samples were first placed for 10 minutes on dry
ice before being exposed for 6 minutes to room tem-
perature and thawed within 4 minutes at 40° C
(three-step thawing) at a mean thawing rate of
approximately 15° C/min. Thereafter the prepara-
tions were rinsed in a dish containing 20 ml KH
solution at room temperature to remove the cry-
oprotecting agents.
Temperature measurements. Temperature
courses during freezing and thawing were measured
with type du3s of Ellab a-s (Ellab Instruments,
Copenhagen, Denmark). In these experiments the
tip of a flexible thermoprobe was inserted into a 15
mm long segment of human IMA and fixed there by
a cotton thread. The preparation was then frozen
and thawed as described previously while tempera-
ture measurements were recorded digitally every 15
seconds.
Organ bath studies. After thawing was per-
formed, the arterial segments were cut into rings
(approximately 2 mm long), mounted between two
hooks of stainless steel wire (diameter 0.15 mm),
suspended in 10 ml organ baths containing KH
solution at 37° C, and gassed continuously with 5%
CO2 in oxygen as described previously.4,8 Changes
in the tone of the preparations were recorded iso-
metrically under a resting tension of 1 gm with
electromechanical transducers (Statham model UC
3) and a potentiometric recorder. At the beginning
of the experiments the rings were stretched to an ini-
tial tension of approximately 2 gm and allowed to
relax and equilibrate for approximately 2 to 3 hours
in the bathing medium. During this time the vascu-
lar preparations were challenged once with nora-
drenaline (1 m mol/L), and the baseline tension of
the rings was readjusted to 1 gm if required.
Concentration-response curves for agonists were
determined by cumulative additions, the concentra-
tion being increased when the maximum effect had
been produced by the previous concentration.
Responses to contracting agonists were expressed in
grams or as percentages of the maximal effects of the
control curves. In these experiments the contractile
response of each arterial ring to noradrenaline (3
m mol/L) or prostaglandin F2a (PGF2a ) (30 m mol/L)
was first determined, and this effect was taken as a
point of comparison for subsequent responses.
During repeated changes of the bathing solution at
15-minute intervals the arteries were allowed to
relax before cumulative concentration-response
curves for the agonist under investigation were
determined without and in the presence of the
antagonist added 20 minutes before the first admin-
istration of the agonist. Experiments with dihy-
dropyridine derivatives and phorbol 12,13-dibu-
tyrate (PDBu) were performed in organ baths pro-
tected from light to avoid inactivation of the
compounds. When responses to relaxant agonists
were investigated, active tone was induced by the
addition of 10 nmol/L U46619, which elicited a
stable contraction of approximately 50% of its maxi-
mum. At the end of these concentration-response
curves, papaverine (300 m mol/L) or sodium nitro-
prusside (100 m mol/L) was added to induce com-
plete relaxation of the rings. This effect was taken as
100% relaxation.
Drugs. The following drugs were used: (-)-
noradrenaline hydrogentartrate, acetylcholine chlo-
ride (Fluka, Buchs, Switzerland), indomethacin,
nifedipine, PDBu (phorbol 12, 13-dibutyrate), sodi-
um nitroprusside dihydrate, U46619 (9,11-
dideoxy-11 a ,9 a -epoxymethanoprostaglandin F2 a ),
staurosporine (Sigma, Munich, FRG), and PGF2 a
(Upjohn, Crawley, U.K.). The calcium channel
opener 209-266 ((+)-(S) enantiomer of isopropyl 4-
(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-
dimethyl-5-nitro3-pyridinecarboxylate) was synthe-
sized as described previously at Sandoz Pharma Ltd.
(Basel, Switzerland).9 Nifedipine, 209-266, and
U46619 were dissolved in ethanol to give a 
1 mmol/L solution containing 60% ethanol.
Staurosporine and PDBu were dissolved in Me2SO.
Samples of 0.1 mmol/L PDBu and 0.01 mmol/L
staurosporine, each containing 1% Me2SO and sam-
ples of 10 m mol/L U46619, were stored at -20° C
until use.
Data analysis. Concentration-response curves
were analyzed with a computer program in RS/1
(BBN Software Products Corporation, Cambridge,
Mass.), and Emax (maximal effects) and pD2 values
(negative logarithm of the molar concentration of
the agonists producing 50% of Emax) were derived
from this analysis. For insurmountable antagonism
apparent pD’2 values (negative logarithm of the
molar concentration of the antagonist reducing the
maximum effect of the agonist by 50%) were calcu-
lated according to the equation pD’2 = pD’x + log(x-
1), where x is the ratio of Emax of the agonist in the
absence and presence of the antagonist and pD’x is
the negative logarithm of the molar concentration of
the antagonist used. One-way analysis of variance
(ANOVA) was performed, followed by the
Bonferroni-corrected t test to assign differences to
individual between-group comparisons when overall
significance (p < 0.05) was attained. Data are pre-
sented as mean ± SEM.
RESULTS
Thawing experiments. A first series of experi-
ments was performed to investigate the influence of
three different thawing protocols on the postthaw
contractile activity of arteries that had been frozen
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Fig. 1. Temperature changes recorded within the lumen
of a human IMA during freezing (left) and thawing at var-
ious procedures (right) while suspended in KH solution
containing 1.8 mol/L Me2SO and 0.1 mol/L sucrose.
Freezing was performed as described in Methods. For
thawing samples were removed from liquid nitrogen (LN)
and thawed either rapidly by placing ampoules for 4 min-
utes into 40° C water bath (1), or samples were first
exposed for 6 minutes to room temperature followed by
thawing within 4 minutes in 40° C water bath (2), or sam-
ples were placed for 10 minutes on dry ice before being
exposed during 6 minutes to room temperature followed
by 4-minute thawing in 40° C water bath (3). Each curve
represents mean of four recordings (single lines), extrapo-
lated to -196° C (dotted lines).
after 10-minute equilibration with the cryomedium.
Temperature changes during cooling and these three
thawing protocols, recorded inside the lumen of a
human IMA, are illustrated in Fig. 1. After thawing
was performed, the maximal contractile responses to
noradrenaline were generally diminished by 40% to
60% when compared with those of the unfrozen
control group. Although the differences between
maximal noradrenaline effects after the three thaw-
ing procedures were not significant, postthaw con-
tractile responsiveness to noradrenaline of slowly
thawed arteries appeared to be slightly better than in
rapidly thawed tissues (Fig. 2., top, Table I).
Therefore all samples used in the subsequent exper-
iments were thawed slowly according to the three-
step thawing protocol.
Equilibration experiments. In a second series
of experiments the postthaw functional recovery of
human IMA after different prefreezing equilibration
times of the tissues with the cryomedium were inves-
tigated. Prefreezing equilibration with the cry-
omedium for 10, 60, and 120 minutes at room tem-
perature reduced the maximal contractile responses
to noradrenaline to approximately 60% of that pro-
duced by unfrozen arteries, and no differences were
seen among these three groups. Equilibration for
240 minutes with the cryomedium before the freez-
ing process was begun reduced the postthaw con-
tractility markedly to 25% of that obtained with
unfrozen tissues (Fig. 2, bottom, Table I). As indi-
cated by the calculated pD2 values, noradrenaline
consistently stimulated cryopreserved IMA at
approximately two to three times lower concentra-
tions than those of the unfrozen control group, sug-
gesting a postthaw sensitization to a -adrenoceptor-
mediated contractile responses of the arterial
smooth muscle. In contrast, neither efficacy nor
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Fig. 2. Concentration-response curves for noradrenaline
on rings from human IMA without (solid circles, n = 50)
and after cryopreservation. Responses are expressed in
grams; bars represent mean ± SEM. Top: After 10-minute
equilibration with cryomedium before cryopreservation,
thawing was achieved within 4 minutes in 40° C water
bath without (one-step, empty squares, n = 12), after 6-
minute exposure to room temperature (two-step, solid
squares, n = 12), or after 10-minute exposure to dry ice
followed by 6-minute exposure to room temperature
(three-step, empty circles, n = 12). Bottom: Samples were
cryopreserved after equilibration with cryomedium at
room temperature for 10 minutes (empty circles, n = 12),
60 minutes (solid squares, n = 30), 120 minutes (empty
squares, n = 12), and 240 minutes (solid triangles, n = 12)
and thawed according to three-step thawing procedure.
Fig. 3. Concentration-response curves for PDBu on rings
from human IMA without (solid circles, n = 32) and after
cryopreservation after equilibration with cryomedium at
room temperature for 10 minutes (empty circles, n = 10),
60 minutes (solid squares, n = 30), 120 minutes (empty
squares, n = 10), and 240 minutes (solid triangles, n = 10).
Responses are expressed in grams; bars represent mean ±
SEM.
potency of noradrenaline was changed if arterial
smooth muscle preparations had been equilibrated
at room temperature for 60 minutes with the cry-
omedium without freezing (n = 5, not illustrated).
When contractile responses of human IMA were
elicited through direct activation of PKC by PDBu,
maximal contractile responses to PDBu of arteries
that had been frozen after 10 and 60 minutes equi-
libration with the cryomedium were similar to those
of unfrozen control arteries. Only prolonged expo-
sure for 120 and 240 minutes to the cryomedium
before the cooling process was begun attenuated
maximal contractile responses to PDBu. However,
in all groups of cryopreserved IMA the concentra-
tion-response curves to PDBu were shifted to the
left by a factor of 4 to 9 when compared with those
of unfrozen control tissues. Maximal sensitization to
stimulation by PDBu was observed in arteries that
had been equilibrated for 60 minutes with the cry-
omedium before the freezing process was started
(Fig. 3, Table I).
Antagonism by staurosporine. Experiments
with antagonists were performed with tissues that
had been frozen after 60-minute equilibration with
the cryomedium, the data being compared with
those determined on unfrozen arteries. In both
unfrozen and cryopreserved arteries contractile
responses to PDBu were attenuated when the PKC
inhibitor staurosporine was present in the bathing
fluid. Responses to PDBu of cryopreserved arteries
(Fig. 4, top) were slightly but significantly more sus-
ceptible to inhibition by staurosporine than
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Table I. Postthaw parameters (Emax and pD2 values) for contractile responses to noradrenaline and PDBu
of rings from human internal mammary arteries after various thawing rates and prefreezing equilibration
times with the cryomedium
Equilibration/thawing Noradrenaline n PDBu n
Emax (gm)
Unfrozen IMA 1.97 ± 0.17 50 1.45 ± 0.11 32
10 min/one-step 0.76 ± 0.11* 12
10 min/two-step 0.95 ± 0.25* 12
10 min/three-step 1.19 ± 0.26 12 1.32 ± 0.21 10
60 min/three-step 1.20 ± 0.16* 30 1.57 ± 0.24 30
120 min/three-step 1.11 ± 0.20* 12 0.77 ± 0.10*† 10
240 min/three-step 0.47 ± 0.09*† 12 0.71 ± 0.16*† 10
pD2 value
Unfrozen IMA 6.55 ± 0.06 50 7.36 ± 0.07 32
10 min/one-step 6.79 ± 0.12 12
10 min/two-step 6.98 ± 0.09* 12
10 min/three-step 7.16 ± 0.08* 12 8.05 ± 0.17* 10
60 min/three-step 7.13 ± 0.06* 30 8.31 ± 0.09* 30
120 min/three-step 7.24 ± 0.07* 12 8.38 ± 0.08* 10
240 min/three-step 7.12 ± 0.09* 12 8.33 ± 0.06* 10
pD2 value = negative logarithm of the molar concentration of an agonist producing 50% of maximum response.
*Significant differences against values determined in unfrozen tissues.
†Significant differences against values determined in tissues frozen after 10-, 60-, and 120-minute equilibration and thawed according
to the three-step protocol. Data are given as mean ± SEM.
Table II. Apparent pD’2 values for antagonism of PDBu and noradrenaline in rings from human internal
mammary arteries cryopreserved after 60 minutes of prefreezing equilibration with the cryomedium and in
unfrozen control arteries
Cryopreserved Difference
IMA n Unfrozen IMA n significant
PDBu - Staurosporine 7.65 ± 0.10 15 7.30 ± 0.08 12 p < 0.01
NA - Staurosporine 6.72 ± 0.09 13 6.74 ± 0.09 10 NS
NA - Nifedipine 7.75 ± 0.15 8 7.50 ± 0.10 6 NS
pD’2 value = negative logarithm of the molar concentration of an antagonists that reduces the maximal effect of the agonist by 50%.
Data are given as mean ± SEM.
NA, Noradrenaline; NS, not significant.
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unfrozen tissues (Fig. 4, bottom). As indicated by
the calculated pD’2 values (Table II), approximately
two times lower concentrations of staurosporine
were sufficient to antagonize responses of cryopre-
served IMA to PDBu to the same extent as in the
unfrozen control group. When tested against nora-
drenaline, staurosporine proved to be equipotent in
both cryopreserved and unfrozen arteries (Table II).
Modification of calcium influx. Contractile
responses of cryopreserved IMA to PDBu proved to
be highly susceptible to blockade of calcium influx
by nifedipine. In the presence of 3 and 30 nmol/L
nifedipine, the concentration-response curve to
PDBu was shifted to the right in a concentration-
dependent manner. However, a 100 times higher
concentration of the calcium channel blocker (3
m mol/L) elicited no further attenuation of the
PDBu effects (Fig. 5, top). On cryopreserved IMA
in the presence of 3 m mol/L nifedipine, PDBu pro-
duced a pD2 value of 7.17 ± 0.03 (n = 5), which was
not different from the pD2 value (7.07 ± 0.15, n =
4) determined on unfrozen control arteries in this
series. In contrast, the same nifedipine concentration
(3 m mol/L) did not modify responses to PDBu
when tested on unfrozen human IMA (Fig. 5, bot-
tom, Table III). When tested against noradrenaline,
nifedipine (3 and 30 nmol/L) was equipotent on
both cryopreserved and unfrozen IMA with similar
pD’2 values (Table II).
When concentration-response curves for PDBu
were determined in the presence of the calcium
channel opener 209-266 (100 nmol/L), a signifi-
Fig. 4. Concentration-response curves for PDBu on rings
from human IMA cryopreserved after 60-minute equili-
bration with cryomedium at room temperature (top) and
on unfrozen controls (bottom) without (solid circles) and
in presence of staurosporine, 5 nmol/L (empty circles), 20
nmol/L (solid squares), 30 nmol/L (solid triangles), and
100 nmol/L (empty squares) added 20 minutes before
agonist. Effects are expressed as percentages of controls;
bars represent mean ± SEM from five to six individual
experiments.
Fig. 5. Concentration-response curves for PDBu on rings
from human IMA cryopreserved after 60-minute equili-
bration with cryomedium at room temperature (top) and
on unfrozen controls (bottom) without (solid circles) and
in presence of nifedipine, 3 nmol/L (empty circles), 30
nmol/L (solid squares), and 3 m mol/L (empty squares)
added 20 minutes before agonist. Effects are expressed as
percentages of controls; bars represent mean ± SEM from
four to five individual experiments.
cant shift to the left occurred in the concentration-
response in both cryopreserved and unfrozen arter-
ies (Table III). In contrast, neither in unfrozen nor
in cryopreserved IMA did 209-266 modify contrac-
tile responses to a -adrenoceptor stimulation with
noradrenaline (Table III).
Blockade of endogenous prostaglandin syn-
thesis. To investigate whether the time of prefreez-
ing exposure to the Me2SO-containing medium
would modify endogenously synthesized prosta-
glandins, concentration-response curves to PGF2 a
were determined without and after blockade of
endogenous prostaglandin synthesis by indo-
methacin on unfrozen IMA and on arteries that had
been cryopreserved after 10 and 60 minutes of equi-
libration with the cryomedium (Fig. 6). After block-
ade of the endogenous prostaglandin synthesis was
achieved with 1 m mol/L indomethacin, responses to
PGF2 a of unfrozen IMA were enhanced but
unchanged in cryopreserved arteries (Table III).
Furthermore no statistical differences were seen
between the calculated pD2 values for PGF2a in cry-
opreserved IMA and in unfrozen arteries after
blockade of endogenous prostaglandin synthesis
(Fig. 6, Table III).
Relaxant responses. Endothelium-independent
relaxant responses to sodium nitroprusside,
expressed as percentages of the maximal responses to
300 m mol/L papaverine, occurred in cryopreserved
human IMA (pD2 = 6.83 ± 0.07, n = 8) within the
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Fig. 6. Concentration-response curves for (PGF2a ) on rings from human IMA, unfrozen (left)
and cryopreserved after 10-minute (middle) and 60-minute equilibration with cryomedium
(right) at room temperature. Responses to PGF2a were determined without (solid circles) and in
presence of indomethacin, 1 m mol/L (empty circles) added 20 minutes before agonist. Effects are
expressed as percentages of controls; bars represent mean ± SEM from five individual experiments.
Table III. Apparent pD2 values and maximal responses (Emax) of PDBu, noradrenaline, and PGF2a with-
out and in the presence of various antagonists on rings from human IMA cryopreserved after 60-minute
prefreezing equilibration with the cryomedium and in unfrozen control arteries
Cryopreserved IMA Unfrozen IMA
Antagonist conc. pD2 value Emax (%) pD2 value Emax (%)
PDBu - Nifedipine 0 8.37 ± 0.16 100 (8) 7.07 ± 0.15 100 (4)
3 nmol/L 8.30 ± 0.28 85 ± 4 (5)*
30 nmol/L 7.47 ± 0.10* 74 ± 6 (5)*
3 m mol/L 7.17 ± 0.03* 71 ± 8 (5)* 6.99 ± 0.20 103 ± 1 (4)
PDBu - 209-266 0 8.06 ± 0.13 100 (5) 7.23 ± 0.08 100 (8)
100 nmol/L 8.68 ± 0.19* 104 ± 4 (5) 7.53 ± 0.13* 110 ± 3 (8)*
NA - 209-266 0 7.62 ± 0.10 100 (3) 6.65 ± 0.26 100 (5)
100 nmol/L 7.64 ± 0.13 104 ± 2 (3) 6.55 ± 0.13 96 ± 12 (5)
PGF2a - Indomethacin 0 5.82 ± 0.02 100 (5) 5.29 ± 0.09 100 (5)
1 m mol/L 5.74 ± 0.10 80 ± 6 (5) 5.79 ± 0.09* 117 ± 12(5)
Data are presented as mean ± SEM; number of determinations in brackets.
NA, Noradrenaline.
*Significant differences from corresponding control values.
same concentration range as observed in unfrozen
control arteries (pD2 = 6.74 ± 0.06, n = 28).
Moreover, postthaw maximal relaxant effects (Emax
= 92% ± 2%, n = 8) were slightly but significantly
enhanced when compared with those observed in
unfrozen control tissues (Emax = 79% ± 3%, n = 28,
p < 0.05).
In contrast, endothelium-mediated relaxant
responses to acetylcholine, expressed as percentages
of the maximal responses to sodium nitroprusside,
proved to be significantly (p < 0.001) attenuated
after cryopreservation. Compared with unfrozen
IMA (Emax = 71% ± 4%, n = 4), maximal relaxation
in response to acetylcholine was diminished by
approximately 60% (Emax = 26% ± 5%, n = 4) when
tested in arteries that had been cryopreserved after
60-minute equilibration with the cryomedium. In
arteries that had been equilibrated with the cry-
omedium for 60 minutes at room temperature with-
out subsequent freezing, the endothelium-depen-
dent responses to acetylcholine were unchanged (n
= 5, not illustrated).
DISCUSSION
Recent experiments on rabbit carotid arteries have
demonstrated that the clinically observed phenome-
non of fractures in cryopreserved vascular grafts
occurs during rapid rewarming, but not if thawing is
performed slowly.6,7,10 Therefore it was interesting
whether the speed of thawing could also modify the
postthaw functional activity of human arteries as
assessed in pharmacologic testing. In this study thaw-
ing of cryopreserved human IMA at rates ranging
from 15° C/min to 100° C/min had surprisingly lit-
tle effect on the postthaw contractile activity, as indi-
cated by a fairly similar displacement of the concen-
tration-response curves to noradrenaline. It may be,
however, that the predominantly circumferential loca-
tion6 of eventual fractures are of minor importance if
contractions are recorded on arterial ring prepara-
tions, as was done in this study. Nevertheless, the data
suggested that the postthaw contractile responsive-
ness to noradrenaline of slowly thawed arteries was
slightly better than in rapidly thawed samples.
Previous experiments with canine femoral arteries
have demonstrated that prolonged prefreezing equili-
bration with a Me2SO-containing medium reduces
progressively maximal contractile responses to nora-
drenaline without changing the sensitivity to the cat-
echolamine.8 However, despite a generally dimin-
ished efficacy of noradrenaline, the present experi-
ments on human IMA revealed a significant shift to
the left of the noradrenaline curve in most cryopre-
served arteries, indicating increased sensitivity to a -
adrenoceptor stimulation after cryopreservation.
A significant shift to the left of the concentra-
tion-response curve to noradrenaline in human
IMA has also been reported after mechanical
removal of the endothelial cells.11,12 It is well
known that in human IMA endothelial cells con-
tribute to the local control of vascular tone and
modulate agonist-induced contractile responses of
the arterial smooth muscle by secreting relaxing fac-
tors such as prostacyclin13 and endothelium-derived
relaxing factor(s).11,12,14-16 Indeed, previous exper-
iments on human mesenteric and coronary arteries
have demonstrated that cryopreservation under the
conditions used in this study induces considerable
impairment of endothelial morphologic characteris-
tics and function.4 The marked attenuation of
endothelium-mediated relaxant responses to acetyl-
choline in this study therefore suggested that the
enhanced sensitivity to noradrenaline as indicated
by a shift to the left of the concentration-response
curve resulted from cryoinjury of the endothelial
cell function. Further evidence for this result was
presented by the finding that blockade of endoge-
nous prostaglandin synthesis by indomethacin
enhanced responses to PGF2 a in unfrozen but not
in cryopreserved arteries, thereby supporting the
contention of a modulatory role of endothelium-
secreted prostaglandins with relaxant activity in
unfrozen human IMA.13
The presence of endothelium has also been asso-
ciated with impaired 45Ca2+ influx through receptor
operated calcium channels into the vascular smooth
muscle, because in rat aorta removal of the endothe-
lium enhances both noradrenaline-induced contrac-
tile responses and noradrenaline-dependent 45Ca2+
influx.17 However, in this study the effects of nora-
drenaline were equally susceptible to inhibition of
calcium influx by nifedipine in both unfrozen and
cryopreserved tissues. Furthermore in both
unfrozen and cryopreserved samples, responses to
noradrenaline were unchanged in the presence of
the calcium channel opener 209-266 at a concentra-
tion (100 nmol/L) that has been shown to enhance
45Ca2+ uptake and to promote contractile responses
of canine saphenous veins to depolarization.18
Hence, these data did not support the presumption
that the modified postthaw sensitivity of cryopre-
served IMA to noradrenaline resulted from cryoin-
jury of the endothelial cells.
Experiments with isolated canine femoral and
coronary arteries have demonstrated that during stim-
ulation with PDBu both release and action of
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endothelium-derived relaxing factor(s) on the vascu-
lar smooth muscle are inhibited.19 Therefore it might
be possible that the postthaw attenuation of endothe-
lium-dependent relaxant response to acetylcholine of
human IMA in these experiments reflects activation of
PKC induced by the freezing/thawing process. This
mechanism could also explain the enhanced sensitivi-
ty to noradrenaline of frozen/thawed IMA. 
Therefore further experiments were performed
to investigate whether changes in transmembrane
signaling mechanisms had contributed to the modi-
fied postthaw noradrenaline effects. Contractile
responses to noradrenaline of human IMA are medi-
ated predominantly through a 1-adrenoceptors.15,20
Stimulation of a 1-adrenoceptors is thought to acti-
vate pertussis sensitive guanine nucleotide binding
proteins (G proteins), leading to increased calcium
influx and activation of phospholipase C. Phos-
pholipase C then catalyzes the breakdown of phos-
phoinositide 4,5-bisphosphate to inositol 1,4,5-
triphosphate and diacylglycerol, causing release of
calcium from intracellular stores and activation of
PKC, respectively.21 Furthermore a negative feed-
back control of vascular contraction with activation
of PKC may inhibit the formation of inositol 1,4,5-
triphosphate.22 Against this background activation
of PKC could well explain the attenuated maximal
responses to noradrenaline of cryopreserved IMA
observed in this study. Indeed, phorbolesters have
been reported to attenuate contractions of rat aorta
in response to noradrenaline23 and 5-hydroxytrypt-
amine associated with inhibition of phosphoinositide
turnover.24
PDBu stimulates PKC by acting at the same site
as diacylglycerol.22,25 Therefore PDBu was selected
to assess the extent of activation of PKC in human
IMA without and after cryopreservation. In arteries
that had been equilibrated with the cryomedium for
different times before freezing, a time-dependent
shift to the left of the PDBu curve without reduc-
tion of the maximal contractile effects was observed.
Maximal sensitization to PDBu-induced contrac-
tions was found in arteries that had been equilibrat-
ed for 60 minutes with the cryomedium before the
cooling process was started. Therefore these arteries
were used to investigate changes in transmembrane
signaling after cryopreservation. Staurosporine, a
potent though nonspecific inhibitor of PKC,26,27
antagonized responses to PDBu in both cryopre-
served and unfrozen IMA, being slightly more
potent in cryopreserved tissues. Besides indicating
that the contractile responses to PDBu were indeed
mediated through PKC, these findings suggested an
activation of PKC by the cryopreservation process.
Furthermore PDBu-induced contractile responses of
cryopreserved arteries were highly susceptible to
blockade of calcium entry, whereas in unfrozen tis-
sues PDBu effects proved to be unequivocally resis-
tant to the action of the calcium entry blocker
nifedipine. In cryopreserved arteries, where the con-
centration-response curve of PDBu was markedly
shifted to the left, nifedipine completely restored the
PDBu curve, making it superimposable to that
determined in unfrozen control arteries. Several
studies on animal tissues support the contention that
phorbolesters modulate dihydropyridine-sensitive
calcium conductance through activation of PKC,
thereby increasing transmembrane calcium
influx,22,28-32 presumably by protein phosphoryla-
tion of a calcium channel subunit.33 Animal studies
have also shown that activation of PKC may be ini-
tiated by exposure to a hypertonic solution such as
elevated glucose concentration.30,34 However, in
our studies exposure of human IMA to the cry-
omedium without freezing provided no evidence for
an activation of PKC. Therefore it may be hypothe-
sized that in these experiments activation of PKC
was induced by thermophysical stresses, because
during freezing ice crystals will be dispersed
throughout the tissue.
CONCLUSION
The consensus of evidence suggests that activa-
tion of PKC associated with increased Ca2+ influx
through dihydropyridine-sensitive Ca2+ channels
and reduced production of endogenous relaxing
agents such as endothelium-derived relaxing fac-
tor(s) might be the underlying mechanism of spasms
in cryopreserved vessel grafts. Therefore these data
suggest that postoperative administration of calcium
channel blocking agents should be an effective treat-
ment to prevent the development of spasms in arte-
rial grafts. Moreover, because postthaw vascular
smooth muscle responses to the nitric oxide donor
sodium nitroprusside were unchanged, the use of
long-acting nitrates that relax arteries in an endothe-
lium-independent manner may be useful as long as
endothelial function is impaired. It remains to be
determined how long after grafting these in vitro
observed changes will persist and preventive treat-
ment will be required. These aspects, however, can
be evaluated only in clinical studies.
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